Vismodegib (Erivedge, Genentech-Roche) is the first in class of Hedgehog pathway inhibitors approved for treatment of metastatic basal cell carcinoma (BCC), or locally advanced BCC that has recurred after surgery or is not amenable to surgery or radiation. Its path to discovery has been unique and traces its origin to corn lilies, sheep, Drosophila flies, and the Hedgehog signaling pathway.
|Original language||English (US)|
|Number of pages||3|
|Journal||Journal of Drugs in Dermatology|
|State||Published - May 2018|
ASJC Scopus subject areas